Treatment options for patients with large cell neuroendocrine carcinoma of the lung

General Thoracic and Cardiovascular Surgery

Volumn 62, Issue 6, 2014, Pages 351-356

  Iyoda, Akira ^a   Makino, Takashi ^a   Koezuka, Satoshi ^a   Otsuka, Hajime ^a   Hata, Yoshinobu ^a  

^a TOHO UNIVERSITY   (Japan)

Author keywords

Large cell neuroendocrine carcinoma; Lung; Treatment

Indexed keywords

AMRUBICIN; BEVACIZUMAB; CISPLATIN; ETOPOSIDE; GEFITINIB; IRINOTECAN; NEDAPLATIN; OCTREOTIDE;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL FEATURE; DISEASE ACTIVITY; HUMAN; INTERMETHOD COMPARISON; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG CARCINOMA; MULTIMODALITY CANCER THERAPY; REVIEW; TREATMENT INDICATION; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; CARCINOMA, LARGE CELL; CARCINOMA, NEUROENDOCRINE; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; PROGNOSIS;

EID: 84903771373     PISSN: 18636705     EISSN: 18636713     Source Type: Journal    
DOI: 10.1007/s11748-014-0379-9     Document Type: Review

References (64)

1. Arrigoni MG, Woolner LB, Bernatz PE. Atypical carcinoid tumors of the lung. J Thorac Cardiovasc Surg. 1972;64:413-21.
2. Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler GB Jr, Nieman L, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. Am J Surg Pathol. 1991;15:529-53.
3. World Health Organization. Histological typing of lung and pleural tumours. 3rd ed. Bochum: Springer; 1999.
4. Iyoda A, Hiroshima K, Nakatani Y, Fujisawa T. Pulmonary large cell neuroendocrine carcinoma - its place in the spectrum of pulmonary carcinoma. Ann Thorac Surg. 2007;84:702-7.
5. Travis WD, Rusch W, Flieder DB, Falk R, Fleming MV, Gal AA, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 1998;22:934-44. (Pubitemid 28364493)
6. Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y, et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol. 2006;24:70-6. (Pubitemid 46630496)
7. Iyoda A, Hiroshima K, Baba M, Saitoh Y, Ohwada H, Fujisawa T. Pulmonary large cell carcinomas with neuroendocrine features are high grade neuroendocrine tumors. Ann Thorac Surg. 2002;73:1049-54. (Pubitemid 34275875)
8. Isaka M, Nakagawa K, Ohde Y, Okumura T, Watanabe R, Ito I, et al. A clinicopathological study of peripheral, small-sized high-grade neuroendocrine tumours of the lung: differences between small-cell lung carcinoma and large-cell neuroendocrine carcinoma. Eur J Cardiothorac Surg. 2012;41:841-6.
9. Varlotto JM, Medford-Davis LN, Recht A, Flickinger JC, Schaefer E, Zander DS, et al. Should large cell neuroendocrine lung carcinoma be classified and treated as a small cell lung cancer or with other large cell carcinomas? J Thorac Oncol. 2011;6:1050-8.
10. Asamura H. Identity, similarity, and difference between large cell neuroendocrine carcinoma and small cell carcinoma. J Thorac Oncol. 2011;6:1774.
11. Rossi G, Mengoli MC, Cavazza A. Pulmonary large cell neuroendocrine carcinoma: a true high-grade neuroendocrine tumor needing prospective therapeutic data. J Thorac Oncol. 2011;6:1775.
12. Iyoda A, Baba M, Hiroshima K, Saitoh H, Moriya Y, Shibuya K, et al. Imprint cytologic features of pulmonary large cell neuroendocrine carcinoma: comparison with classic large cell carcinoma. Oncol Rep. 2004;11:285-8.
13. Iyoda A, Hiroshima K, Moriya Y, Mizobuchi T, Otsuji M, Sekine Y, et al. Pulmonary large cell neuroendocrine carcinoma demonstrates high proliferative activity. Ann Thorac Surg. 2004;77:1891-5. (Pubitemid 38686551)
14. Jones MH, Virtanen C, Honjoh D, Miyoshi T, Satoh Y, Okumura S, et al. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet. 2004;363:775-81. (Pubitemid 38315167)
15. Zaffaroni N, De Polo D, Villa R, Della Porta C, Collini P, Fabbri A, et al. Differential expression of telomerase activity in neuroendocrine lung tumours: correlation with gene product immunophenotyping. J Pathol. 2003;201:127-33. (Pubitemid 37121211)
16. Nitadori J, Ishii G, Tsuta K, Yokose T, Murata Y, Kodama T, et al. Immunohistochemical differential diagnosis between large cell neuroendocrine carcinoma and small cell carcinoma by tissue microarray analysis with a large antibody panel. Am J Clin Pathol. 2006;125:682-92.
17. Ullmann R, Petzmann S, Sharma A, Cagle PT, Popper HH. Chromosomal aberrations in a series of large-cell neuroendocrine carcinomas: unexpected divergence from small-cell carcinoma of the lung. Hum Pathol. 2001;32:1059-63. (Pubitemid 33015665)
18. Peng WX, Shibata T, Katoh H, Kokubu A, Matsuno Y, Asamura H, et al. Array-based comparative genomic hybridization analysis of high-grade neuroendocrine tumors of the lung. Cancer Sci. 2005;96:661-7. (Pubitemid 41723542)
19. Hiroshima K, Iyoda A, Shibuya K, Haga Y, Toyozaki T, Iizasa T, et al. Genetic alterations in early-stage pulmonary large cell neuroendocrine carcinoma. Cancer. 2004;100:1190-8. (Pubitemid 38325947)
20. Iyoda A, Hiroshima K, Toyozaki T, Haga Y, Fujisawa T, Ohwada H. Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer. 2001;91:1992-2000. (Pubitemid 32476362)
21. Jiang SX, Kameya T, Shoji M, Dobashi Y, Shinada J, Yoshimura H. Large cell neuroendocrine carcinoma of the lung. A histologic and immunohistochemical study of 22 cases. Am J Surg Pathol. 1998;22:526-37. (Pubitemid 28213738)
22. Takei H, Asamura H, Maeshima A, Suzuki K, Kondo H, Niki T, et al. Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg. 2002;124:285-92. (Pubitemid 35025604)
23. Veronesi G, Morandi U, Alloisio M, Terzi A, Cardillo G, Filosso P, et al. Large cell neuroendocrine carcinoma of the lung: a retrospective analysis of 144 surgical cases. Lung Cancer. 2006;53:111-5. (Pubitemid 43831353)
24. Paci M, Cavazza A, Annessi V, Putrino I, Ferrari G, De Franco S, et al. Large cell neuroendocrine carcinoma of the lung: a 10-year clinicopathologic retrospective study. Ann Thorac Surg. 2004; 77:1163-7. (Pubitemid 38452339)
25. Rossi G, Cavazza A, Marchioni A, Longo L, Migaldi M, Sartori G, et al. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol. 2005;23:8774-85. (Pubitemid 46211523)
26. Battafarano RJ, Fernandez FG, Ritter J, Meyers BF, Guthrie TJ, Cooper JD, et al. Large cell neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer. J Thorac Cardiovasc Surg. 2005;130:166-72. (Pubitemid 40941686)
27. Skuladottir H, Hirsch FR, Hansen HH, Olsen JH. Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtype: a population-based study in Denmark. Lung Cancer. 2002;37:127-35. (Pubitemid 34831803)
28. Iyoda A, Hiroshima K, Moriya Y, Sekine Y, Shibuya K, Iizasa T, et al. Prognostic impact of large cell neuroendocrine histology in patients with pathological stage 1a pulmonary non-small cell carcinoma. J Thorac Cardiovasc Surg. 2006;132:312-5. (Pubitemid 44092842)
29. Iyoda A, Hiroshima K, Moriya Y, Iwadate Y, Takiguchi Y, Uno T, et al. Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma. J Thorac Cardiovasc Surg. 2009;138:446-53.
30. Iyoda A, Jiang SX, Travis WD, Kurouzu N, Ogawa F, Amano H, et al. Clinicopathological features and the impact of the new TNM classification of malignant tumors in patients with pulmonary large cell neuroendocrine carcinoma. Mol Clin Oncol. 2013;1:437-43.
31. Fernandez FG, Battafarano RJ. Large-cell neuroendocrine carcinoma of the lung. Cancer Control. 2006;13:270-5. (Pubitemid 44600938)
32. Kozuki T, Fujimoto N, Ueoka H, Kiura K, Fujiwara K, Shiomi K, et al. Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma. J Cancer Res Clin Oncol. 2005;131:147-51. (Pubitemid 40175007)
33. Iyoda A, Hiroshima K, Toyozaki T, Haga Y, Baba M, Fujisawa T, et al. Adjuvant chemotherapy for large cell carcinoma with neuroendocrine features. Cancer. 2001;92:1108-12. (Pubitemid 32861658)
34. Iyoda A, Hiroshima K, Moriya Y, Takiguchi Y, Sekine Y, Shibuya K, et al. Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma. Ann Thorac Surg. 2006;82:1802-7. (Pubitemid 44584914)
35. Sarkaria IS, Iyoda A, Roh MS, Sica G, Kuk D, Sima CS, et al. Neoadjuvant and adjuvant chemotherapy in resected pulmonary large cell neuroendocrine carcinomas: a single institution experience. Ann Thorac Surg. 2011;92:1180-6.
36. Saji H, Tsuboi M, Matsubayashi J, Miyajima K, Shimada Y, Imai K, et al. Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy. Anticancer Drugs. 2010;21:89-93.
37. Abedallaa N, Tremblay L, Baey C, Fabre D, Planchard D, Pignon JP, et al. Effect of chemotherapy in patients with resected small-cell or large-cell neuroendocrine carcinoma. J Thorac Oncol. 2012;7:1179-83.
38. Tanaka Y, Ogawa H, Uchino K, Ohbayashi C, Maniwa Y, Nishio W, et al. Immunohistochemical studies of pulmonary large cell neuroendocrine carcinoma: a possible association between staining patterns with neuroendocrine markers and tumor response to chemotherapy. J Thorac Cardiovasc Surg. 2013;145:839-46.
39. Sun JM, Ahn MJ, Ahn JS, Um SW, Kim H, Kim HK, et al. Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer? Lung Cancer. 2012;77:365-70.
40. Igawa S, Watanabe R, Ito I, Murakami H, Takahashi T, Nakamura Y, et al. Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer. Lung Cancer. 2010;68:438-45.
41. Tokito T, Kenmotsu H, Watanabe R, Ito I, Shukuya T, Ono A, et al. Comparison of chemotherapeutic efficacy between LCNEC diagnosed using large specimens and possible LCNEC diagnosed using small biopsy specimens. Int J Clin Oncol. 2012;19 (Epub ahead of print).
42. Shimada Y, Niho S, Ishii G, Hishida T, Yoshida J, Nishimura M, et al. Clinical features of unresectable high-grade lung neuroendocrine carcinoma diagnosed using biopsy specimens. Lung Cancer. 2012;75:368-73.
43. Yamazaki S, Sekine I, Matsuno Y, Takei H, Yamamoto N, Kunitoh H, et al. Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy. Lung Cancer. 2005;49:217-23. (Pubitemid 40966750)
44. Le Treut J, Sault MC, Lena H, Souquet PJ, Vergnenegre A, Le Caer H, et al. Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. Ann Oncol. 2013;24:1548-52.
45. Niho S, Kenmotsu H, Sekine I, Ishii G, Ishikawa Y, Noguchi M, et al. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study. J Thorac Oncol. 2013;8:980-4.
46. Fournel L, Falcoz PE, Alifano M, Charpentier MC, Boudaya MS, Magdeleinat P, et al. Surgical management of pulmonary large cell neuroendocrine carcinomas: a 10-year experience. Eur J Cardiothorac Surg. 2013;43:111-4.
47. Kenmotsu Y, Oshita F, Sugiura M, Murakami S, Kondo T, Saito H, et al. Nedaplatin and irinotecan in patients with large-cell neuroendocrine carcinoma of the lung. Anticancer Res. 2012; 32:1453-6.
48. Yoshida H, Sekine I, Tsuta K, Horinouchi H, Nokihara H, Yamamoto N, et al. Amrubicin monotherapy for patients with previously treated advanced large-cell neuroendocrine carcinoma of the lung. Jpn J Clin Oncol. 2011;41:897-901.
49. De Pas TM, Giovannini M, Manzotti M, Trifirò G, Toffalorio F, Catania C, et al. Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib. J Clin Oncol. 2011;29:e819-22.
50. Yanagisawa S, Morikawa N, Kimura Y, Nagano Y, Murakami K, Tabata T. Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: possible transformation of lung adenocarcinoma. Respirology. 2012;17:1275-7.
51. Sakai Y, Yamasaki T, Kusakabe Y, Kasai D, Kotani Y, Nishimura Y, et al. Large-cell neuroendocrine carcinoma of lung with epidermal growth factor receptor (EGFR) gene mutation and co-expression of adenocarcinoma markers: a case report and review of the literature. Multidiscip Respir Med. 2013;8:47.
52. Yoshida Y, Ota S, Murakawa T, Takai D, Nakajima J. Combined large cell neuroendocrine carcinoma and adenocarcinoma with epidermal growth factor receptor mutation in a female patient who never smoked. Ann Thorac Cardiovasc Surg. 2013 (Epub ahead of print).
53. Iyoda A, Travis WD, Sarkaria IS, Jiang SX, Amano H, Sato Y, et al. Expression profiling and identification of potential molecular targets for therapy in pulmonary large-cell neuroendocrine carcinoma. Exp Ther Med. 2011;2:1041-5.
54. Filosso PL, Ruffini E, Oliaro A, Rena O, Casadio C, Mancuso M, et al. Large-cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighteen cases and the efficacy of adjuvant treatment with octreotide. J Thorac Cardiovasc Surg. 2005;129:819-24. (Pubitemid 40487883)
55. Odate S, Nakamura K, Onishi H, Kojima M, Uchiyama A, Nakano K, et al. TrkB/BDNF signaling pathway is a potential therapeutic target for pulmonary large cell neuroendocrine carcinoma. Lung Cancer. 2013;79:205-14.
56. Yokouchi H, Kitahashi M, Oshitari T, Yamamoto S. Intravitreal bevacizumab for iris tumor metastasized from large cell neuroendocrine carcinoma of lung. Graefes Arch Clin Exp Ophthalmol. 2013;251:2243-5.
57. Kusafuka K, Ferlito A, Lewis JS Jr, Woolgar JA, Rinaldo A, Slootweg PJ, et al. Large cell neuroendocrine carcinoma of the head and neck. Oral Oncol. 2012;48:211-5.
58. Ose N, Inoue M, Morii E, Shintani Y, Sawabata N, Okumura M. Multimodality therapy for large cell neuroendocrine carcinoma of the thymus. Ann Thorac Surg. 2013;96:e85-7.
59. Tangjitgamol S, Manusirivithaya S, Choomchuay N, Leelahakorn S, Thawaramara T, Pataradool K, et al. Paclitaxel and carboplatin for large cell neuroendocrine carcinoma of the uterine cervix. J Obstet Gynaecol Res. 2007;33:218-24. (Pubitemid 46376407)
60. Embry JR, Kelly MG, Post MD, Spillman MA. Large cell neuroendocrine carcinoma of the cervix: prognostic factors and survival advantage with platinum chemotherapy. Gynecol Oncol. 2011;120:444-8.
61. Yoseph B, Chi M, Truskinovsky AM, Dudek AZ. Large-cell neuroendocrine carcinoma of the cervix. Rare Tumors. 2012;4:e18.
62. Oberstein PE, Kenney B, Krishnamoorthy SK, Woo Y, Saif MW. Metastatic gastric large cell neuroendocrine carcinoma: a case report and review of literature. Clin Colorectal Cancer. 2012;11:218-23.
63. Evans AJ, Humphrey PA, Belani J, van der Kwast TH, Srigley JR. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol. 2006;30:684-93. (Pubitemid 44264993)
64. Shimono C, Suwa K, Sato M, Shirai S, Yamada K, Nakamura Y, et al. Large cell neuroendocrine carcinoma of the gallbladder: long survival achieved by multimodal treatment. Int J Clin Oncol. 2009;14:351-5.